Biography

Prof. Daniele Focosi

Azienda Ospedaliero-Universitaria Pisana, Italy


Email: [email protected]


Qualifications

2006  M.D., University of Pisa, Italy


Publications (Selected）

  1. Focosi, D., Franchini, M., & Casadevall, A. (2026). On the Use of Immunoglobulins for Pre-exposure Prophylaxis Against COVID-19 in Immunocompromised Patients. Infection and Drug Resistance, 19, Article 540925.
  2. Minosse, C., Spezia, P. G., Belladonna, S., et al. (2026). TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses. Vaccines, 14(5), Article 441.
  3. Penic, J., Alfonsi, T., Chillemi, G., et al. (2026). YoyoMut: Interactive Exploration of SARS-CoV-2 Mutation Fixation and Reversion Through Time. Life, 16(5), Article 776.
  4. Spezia, P. G., Cappelli, S., Minosse, C., et al. (2026). Metabolic determinants of torque teno virus load across the diabetes spectrum: insights from a cross-sectional analysis. Scientific Reports, 16, Article 8912.
  5. Focosi, D., Nicastri, E., & Maggi, F. (2026). An Overview of the H5N1 mRNA Vaccine Pipeline (vol 19, e70113, 2025). Influenza and Other Respiratory Viruses, 20(3), Article e12456.
  6. Casadevall, A., Mattoon, E. R., Sullivan, D., et al. (2026). Convalescent plasma for COVID-19: planning for the next pandemic using the worldwide experience. Clinical Microbiology Reviews, 39(1), Article e00060-24.
  7. Franchini, M., Focosi, D., & Mannucci, P. M. (2026). Thrombotic complications in hemophilia: An intricate conundrum. Seminars in Thrombosis and Hemostasis, 52(02), 164–173.
  8. Giuffrida, A. C., Gandini, G., Focosi, D., et al. (2026). Impact of Exercise/Sport on Well-being in von Willebrand Disease and Other Congenital Bleeding Disorders: An Update. Seminars in Thrombosis and Hemostasis. Advance online publication.
  9. Focosi, D. (2026). Special Issue “Influenza Viruses: Infection and Genomics”. International Journal of Molecular Sciences, 27(1), Article 506.
  10. Sullivan, D. J., Reik, R., Prichard, A., et al. (2026). COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval. Expert Review of Anti-infective Therapy. Advance online publication.
  11. Focosi, D., & Maggi, F. (2026). Reassessing sotrovimab's role in COVID-19: insights and implications. The Lancet Infectious Diseases, 26(1), 3–4.
  12. Focosi, D., Franchini, M., Maggi, F., et al. (2025). The Emergence of Escape Mutations in COVID-19 Following Anti-Spike Monoclonal Antibody Treatment: How Do We Tackle It?. Infection and Drug Resistance, 18, 5207–5217.
  13. Tuccori, M., Focosi, D., Arzenton, E., et al. (2025). Acquired Bleeding Disorders Associated With Immune Checkpoint Inhibitors: An Update. Haemophilia. Advance online publication.
  14. Sullivan, D. J., Franchini, M., Joyner, M. J., et al. (2025). A Rapid Systematic Review of US Food and Drug Administration–authorized COVID-19 Treatments. Open Forum Infectious Diseases, 12(11), Article ofaf635.
  15. Maggi, F., & Focosi, D. (2025). Anelloviruses as a marker of immunosuppression and inflammation in different clinical settings. Enfermedades Infecciosas y Microbiología Clínica, 43(9), 552–554.
  16. Zaremba, S., Focosi, D., Pruter, W. W., et al. (2025). COVID-19 convalescent plasma for B-cell depleted patients: a systematic review and individual patient data meta-analysis. Frontiers in Medicine, 12, Article 1658593.
  17. Focosi, D., Casadevall, A., Sullivan, D. J., et al. (2025). The European Conference on Infections in Leukaemia (ECIL-10) guidelines for COVID-19 should take convalescent plasma into proper consideration. Leukemia, 39(9), 2302–2303.
  18. Cavazza, S., Palareti, G., de Gaetano, G., et al. (2025). Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey. Bleeding, Thrombosis and Vascular Biology, 4(3), 45–58.
  19. Sberna, G., Minosse, C., Mija, C., et al. (2025). Evaluation of Torquetenovirus (TTV) Particle Integrity Utilizing PMAxx™. International Journal of Molecular Sciences, 26(13), Article 6542.
  20. Maggi, F., & Focosi, D. (2025). Mpox in DR Congo: a call to action. The Lancet, 406(10498), 7–8.
  21. Focosi, D., & Casadevall, A. (2025). Sipavibart: when a success changes into a failure. The Lancet Infectious Diseases, 25(7), 713–714.


Profiles Details
https://scholar.google.com/citations?user=Qs_HBRQAAAAJ&hl=
https://www.researchgate.net/profile/Daniele-Focosi

WOS ResearcherID: K-6609-2016

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top